Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SYNACT.STthis companySynAct Pharma AB	SEK 15.12	-10.41×	6.78×	0×	-9.46×	-93.4%	0.0%	0.0%	0.0%	-65.1%	-54.7%	-8.4%	0.01×	0.44×	-47.8×	3.31×	0.0%	1	8.31	2	C
CANTA.STCantargia AB (publ)	SEK 1.57	7.08×	3.91×	3.28×	4.91×	1047.8%	99.0%	48.7%	46.4%	55.3%	57.9%	14.4%	0×	-1.83×	11.37×	9.8×	0.0%	5	3.27	4	A
CRAD-B.STC-Rad AB (publ)	SEK 23.70	103.06×	3.12×	2.45×	16.63×	-54.3%	69.2%	10.2%	2.4%	3.0%	8.3%	4.6%	0.03×	-2.92×	49.18×	3.09×	0.0%	4	5.23	4	A-
DMYD-B.STDiamyd Medical AB (publ)	SEK 0.97	-0.58×	0.61×	310.44×	0.62×	98.3%	-478.8%	-54562.9%	-53583.4%	-104.9%	-78.6%	-132.6%	0×	1.21×	-73.88×	9.08×	0.0%	3	-0.68	2	B-
GENO.STGenovis AB	SEK 21.35	59.03×	5.15×	10.84×	34.56×	-59.9%	21.3%	21.3%	18.2%	8.7%	6.8%	2.2%	0.52×	-0.59×	7.29×	7.36×	0.0%	4	8.04	3	B-
IBT-B.STInfant Bacterial Therapeutics AB (publ)	SEK 72.80	-10.43×	6.46×	0×	-7.87×	-89.1%	0.0%	0.0%	0.0%	-61.9%	-58.8%	-10.6%	0×	2.11×	0×	2.72×	0.0%	2	-1.32	1	D+
Peer median	—	7.08×	3.91×	3.28×	4.91×	-54.3%	21.3%	10.2%	2.4%	3.0%	6.8%	2.2%	0×	-0.59×	7.29×	7.36×	0.0%	4	3.27	3	—